Project Grant R03CA300825
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $169K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $680,334 in funding to the Icahn School of Medicine at Mount Sinai to investigate the cellular and molecular mechanisms driving age-associated pro-tumoral myelopoiesis. The 5-year research project aims to elucidate how aging of the immune system, independent of stromal age, promotes inflammation and tumor progression. The researchers will conduct high-dimensional profiling of...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $147,083 to the Icahn School of Medicine at Mount Sinai to conduct research on "Deconstructing Pathogenic Myelopoiesis in Cancer Immunosuppression and Treatment Resistance". The key objectives are to study the epigenetic regulation and priming of regulatory pathways in tumor-educated bone marrow myeloid progenitors, with a focus on understanding how the NRF2 oxidative...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $198,103 to New York University School of Medicine to investigate the role of the immune microenvironment in melanoma bone metastasis. The research aims to define the mechanisms by which melanoma cells colonize the skeletal system and modify the bone microenvironment, as well as explore the interplay between tumor, skeletal, and immune cells during melanoma bone metastasis. The...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $237,023 Project Grant to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop a high-throughput single-cell multi-omic profiling method (named "SHARE-ME-SEQ") that can jointly capture gene expression, chromatin accessibility, and DNA methylation in acute myeloid leukemia (AML) samples. This 3-year grant, running from March 1, 2025 to February 29, 2028, aims to significantly improve the...
- The Icahn School of Medicine at Mount Sinai was awarded a $532,970 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on the role of CD4 helper T cells in promoting anti-tumor immunity and enhancing responses to PD-1 targeted immunotherapies. The 5-year research project aims to define the key cell-intrinsic features and cell interactions of anti-tumor CD4 T cells that can support effective anti-tumor immune responses, with a focus on...
- This federal Project Grant award of $714,317.00 from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), supports research at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York. The goal is to investigate the mechanisms linking epithelial-mesenchymal transition (EMT), anoikis resistance, and the tumor microenvironment in the progression of metastatic castration-resistant prostate cancer. Key research objectives include determining how...
- The National Cancer Institute, a component of the National Institutes of Health, awarded a $684,877 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Icahn School of Medicine at Mount Sinai. The grant will support a multi-scale analysis of the tumor microenvironment in non-muscle invasive bladder cancer to identify novel therapeutic targets for patients resistant to the standard first-line treatment, Bacillus Calmette-Guerin (BCG). The research project aims to generate...
- The National Cancer Institute has awarded a $145,336 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research located in New York. The project, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors", aims to investigate how manipulating the metabolic state of liver macrophages can enhance their ability to present cancer cell antigens and activate CD8+ T cells, thereby overcoming the...
- The National Cancer Institute (NCI) awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate the role of the interferon gamma (IFNγ) signaling pathway in the lung tumor microenvironment and its impact on tumor immunity. The project aims to deconvolute how various components of the IFNγ pathway, including the negative regulator SOCS1, influence immune cell infiltration and response to immune...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $510,431 Project Grant to The Johns Hopkins University to conduct research on recurrence and resistance in the aging melanoma microenvironment. The research aims to uncover how the aging immune microenvironment influences tumor dormancy and therapeutic resistance in melanoma. Key focus areas include understanding the role of aged lung fibroblasts and their impact on melanoma cell dormancy and reactivation through Wnt...